Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
Phase 2 Completed
86 enrolled 16 charts
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Phase 2 Completed
11 enrolled 16 charts
Chile Biliary Longitudinal Study
Completed
4,749 enrolled
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
57 enrolled 9 charts
S1310
Phase 2 Completed
53 enrolled 13 charts
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
8 enrolled 8 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
Phase 2 Completed
33 enrolled 9 charts
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Phase 2 Completed
40 enrolled 16 charts
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Phase 2 Completed
26 enrolled 11 charts
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Phase 2 Completed
56 enrolled 9 charts
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
Phase 3 Completed
360 enrolled
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
Phase 2 Completed
78 enrolled
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Phase 1 Completed
15 enrolled
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
24 enrolled
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase 1 Completed
36 enrolled
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
48 enrolled
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Phase 2 Completed
50 enrolled
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
Phase 1 Completed
108 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
Phase 1 Completed
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
Phase 1 Completed